| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/04/2002 | EP1235924A1 Antisense modulation of rank expression |
| 09/04/2002 | EP1235900A1 Microparticle-based transfection and activation of dendritic cells |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235851A2 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 09/04/2002 | EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235844A1 28 human secreted proteins |
| 09/04/2002 | EP1235838A1 23 human secreted proteins |
| 09/04/2002 | EP1235825A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 09/04/2002 | EP1235824A1 Vitamin d analogues |
| 09/04/2002 | EP1235814A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 09/04/2002 | EP1235812A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 09/04/2002 | EP1235797A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 09/04/2002 | EP1235793A2 Vla-4 integrin antagonists |
| 09/04/2002 | EP1235777A2 Vitamin d analogues |
| 09/04/2002 | EP1235776A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 09/04/2002 | EP1235596A2 Use of lytic toxins and toxin conjugates |
| 09/04/2002 | EP1235594A2 Inhibition of secretion from non-neuronal cells |
| 09/04/2002 | EP1235592A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-$g(a) AND CD95L IN A MEDICAMENT |
| 09/04/2002 | EP1235586A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 09/04/2002 | EP1235579A1 Pharmaceutical compositions comprising trimegestone |
| 09/04/2002 | EP1235577A2 Protease inhibitors |
| 09/04/2002 | EP1157028B1 Novel substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them |
| 09/04/2002 | EP1054886B1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
| 09/04/2002 | EP0920309B1 Conjugated linoleic acid to maintain or enhance bone mineral content |
| 09/04/2002 | EP0809636B1 Substituted isoxazoles for the treatment of inflammation |
| 09/04/2002 | EP0764208B1 Bmp-9 compositions |
| 09/04/2002 | CN1367793A Neuromedin B and somatostatin receptor agonists |
| 09/04/2002 | CN1367792A Somatostatin agonists |
| 09/04/2002 | CN1367791A Novel angiogenesis inhibitor |
| 09/04/2002 | CN1367787A Water soluble SDZ-RAD esters |
| 09/04/2002 | CN1367701A Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 09/04/2002 | CN1367699A Composition containing extracts of butyrospermum parkii and use as medicament or dietary supplement |
| 09/04/2002 | CN1367695A Phthalazine derivatives for treating inflammatory diseases |
| 09/04/2002 | CN1367693A Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and method of using the same |
| 09/04/2002 | CN1367687A Calcilytic compounds |
| 09/04/2002 | CN1367017A Application of transitional scorpion toxin BmK abT |
| 09/04/2002 | CN1367008A Medicine preparation for curing rheumatism |
| 09/04/2002 | CN1366999A Guzhifengshi liquor for curing osteopathy and rheumatism |
| 09/04/2002 | CN1366991A Application of plant extract for preparing medicine to cure bone absorption increment diseases |
| 09/04/2002 | CN1366977A Nano Guloushan dieda preparation medicine and preparation method |
| 09/04/2002 | CN1366964A Nano Fangji Guanjie prepartion medicine and preparation method |
| 09/04/2002 | CN1366958A Nano Dieda Huoxue preparation medicine for curing traumatic injuries and preparation method |
| 09/04/2002 | CN1366952A Nano Fengshi Guanjie preparation medicine and preparation method |
| 09/04/2002 | CN1366951A Nano Fengshi Maqian preparation medicine and preparation method |
| 09/04/2002 | CN1366926A Nano Hufeng preparation medicine and preparation method |
| 09/04/2002 | CN1090189C Pyrazolopyrimidines type compound |
| 09/04/2002 | CN1090178C Tricyclic compounds having activity specific for integrins, particularly alpha V beta 3 integrins, method for preparing same |
| 09/04/2002 | CN1090177C Preparation of aromatic nitriles |
| 09/03/2002 | USRE37828 Treatment and prevention of adhesions |
| 09/03/2002 | US6444832 Osteoporosis |
| 09/03/2002 | US6444803 Bone mineralization proteins, DNA, vectors, expression systems |
| 09/03/2002 | US6444696 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 09/03/2002 | US6444688 Compounds and compositions with nitrogen-containing non-basic side chains |
| 09/03/2002 | US6444679 Neurological and gastrointestinal disorders; delta opioid ligands or opioid receptors |
| 09/03/2002 | US6444677 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/03/2002 | US6444671 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/03/2002 | US6444642 Administering to mammal effective amount of neuregulin polypeptide with p185.sup.erbb2 protein binding activity to stimulate myogenesis of muscle cells |
| 09/03/2002 | US6444639 Human chorionic gonadotrophin (hcg) used to treat or prevent tumors, multiple sclerosis, inflammation or angiogenesis-dependent diseases |
| 09/03/2002 | US6444443 Gene |
| 09/03/2002 | US6444431 Angiostatin receptor |
| 09/03/2002 | CA2237189C 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 09/03/2002 | CA2140626C Hydroxamic acid derivatives as metalloproteinase inhibitors |
| 08/29/2002 | WO2002066978A2 Detection of compounds that modulate inflammatory responses |
| 08/29/2002 | WO2002066681A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 08/29/2002 | WO2002066667A1 Glucosamine and method of making glucosamine from microbial biomass |
| 08/29/2002 | WO2002066647A2 Type 2 ctokine receptor and nucleic acids encoding same |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066635A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof |
| 08/29/2002 | WO2002066624A2 Novel human protease and polynucleotides encoding the same |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066512A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 08/29/2002 | WO2002066494A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 08/29/2002 | WO2002066481A1 Pyrimidine derivatives for inhibition of cell-proliferation |
| 08/29/2002 | WO2002066475A2 Tricyclic androgen receptor modulator compounds |
| 08/29/2002 | WO2002066463A1 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors |
| 08/29/2002 | WO2002066461A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/29/2002 | WO2002066460A1 Chemical compounds |
| 08/29/2002 | WO2002066458A2 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry |
| 08/29/2002 | WO2002066450A2 Anthrone derivatives and their use as ink inhibitors |
| 08/29/2002 | WO2002066430A1 Tryptase inhibitors |
| 08/29/2002 | WO2002066420A2 Tryptase inhibitors |
| 08/29/2002 | WO2002066063A1 Remedies for metabolic bone diseases |
| 08/29/2002 | WO2002066051A1 Use of the g-csf as adjuvant treatment in connective tissue recontruction |
| 08/29/2002 | WO2002066030A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | WO2002066028A2 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids |
| 08/29/2002 | WO2002065984A2 Compounds having retinoid-like activity |
| 08/29/2002 | WO2002065859A1 Emulsions and aqueous dispersions of phytosterols |
| 08/29/2002 | WO2002042273A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002028858A3 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 08/29/2002 | WO2002022621A3 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 08/29/2002 | WO2002022620A3 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002015894A3 Use of vitamin d derivatives as bone resorption inhibitors |
| 08/29/2002 | WO2002000227A3 Use of lanthanum compounds for the treatment of bone diseases |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001082975A3 Membrane-permeant peptide complexes for medical imaging |
| 08/29/2002 | WO2001079284A3 Therapeutic compounds and methods for formulating v3, a versican isoform |
| 08/29/2002 | WO2001068848A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/29/2002 | WO2001060408A3 Microcompetiton and human disease |
| 08/29/2002 | WO2001012584A3 Pharmaceutical compounds |